[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shiyou Wei\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":154},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,72,101,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100652828","90-effective-infusion-time-of-sufentanil-to-prevent-induction-cough-a-biased-coin-sequential-study-100652828",false,"NCT07778953","90% Effective Infusion Time of Sufentanil to Prevent Induction Cough: A Biased Coin Sequential Study","Determination of the 90% Effective Infusion Time of Sufentanil to Prevent Sufentanil-Induced Cough During General Anesthesia Induction in Young and Elderly Patients: A Biased Coin Design Up-and-Down Sequential Study","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Aged ≥18 ears old\n* Scheduled for elective surgery requiring general anesthesia with tracheal intubation\n\nExclusion Criteria:\n\n* Resting vital signs upon operating-room arrival: systolic blood pressure ≥160 mmHg, or diastolic blood pressure ≥100 mmHg, or heart rate ≥110 beats per minute.\n* Anticipated difficult airway, requirement for rapid-sequence induction, or emergency surgery.\n* Chronic cough, asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, active pulmonary disease, or upper respiratory tract infection within the preceding 2 weeks.\n* Regular opioid use for more than 2 weeks within 6 months before surgery; or recent use of antitussive agents or other medications that may alter the cough reflex.\n* Known history of allergy to study drug (sufentanil citrate).\n* Pregnancy, lactation, psychiatric disorders, or individuals unable to communicate appropriately.","ALL","18 Years","99 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","This single-center, prospective biased coin up-and-down sequential study aims to determine the 90% effective infusion time (ET90) of sufentanil to prevent sufentanil-induced cough (SIC) during the induction phase of general anesthesia in adults undergoing endotracheal intubation. Two age cohorts are studied separately: younger adults (\\\u003C65 years) and older adults (≥65 years). The trial does not test superiority or between-group differences as the primary objective.\n\nAll participants receive sufentanil via a peripheral intravenous pump. The total sufentanil dose is fixed within each age cohort (young: 0.40 μg\u002Fkg; elderly: 0.30 μg\u002Fkg), while the pump injection time is adjusted using the biased coin up-and-down allocation method. SIC success is defined as no audible cough within a prespecified observation window from the start of the infusion until 2 minutes after infusion ends.\n\nThe primary outcome is the ET90 of sufentanil and its 95% confidence interval for each age cohort, estimated using centered isotonic regression with bootstrap confidence intervals. Approximately 120 patients will be screened to obtain at least 54 evaluable participants per cohort.",[27],"Cough",[29,30,31,32],"sufentanil-induced cough","general anesthesia induction","endotracheal intubation","infusion time","NOT_YET_RECRUITING","2026-08-19",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":21},"2026-11-01",{"date":41,"type":21},"2026-12-30",{"name":43,"class":44},"Shiyou Wei","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100650611","ed90-of-tegileridine-for-suppressing-hemodynamic-response-to-tracheal-intubation-a-biased-coin-up-and-down-trial-100650611","NCT07749131","ED90 of Tegileridine for Suppressing Hemodynamic Response to Tracheal Intubation: A Biased Coin Up-and-Down Trial","Determination of the 90% Effective Dose (ED90) of Tegileridine Fumarate for Inhibiting Hemodynamic Stress Response Induced by Tracheal Intubation During General Anesthesia: A Biased Coin Up-and-Down Sequential Study","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Aged ≥18 ears old\n* Scheduled for elective surgery requiring general anesthesia with tracheal intubation\n\nExclusion Criteria:\n\n* Resting Systolic Blood Pressure ≥ 160 mmHg, Diastolic Blood Pressure ≥ 110 mmHg, or heart rate ≥ 110 beats\u002Fmin on admission to operation room\n* Continuous opioid medication use for more than 2 weeks within 6 months before the procedure\n* Known hypersensitivity or allergic reaction to tegileridine, propofol or any excipients of the two drugs\n* Diagnosed psychiatric disorders or inability to communicate and cooperate with study assessment\n* Anticipated difficult airway","90 Years",{"count":55,"type":21},108,[24],"General anesthesia tracheal intubation causes sympathetic activation and hemodynamic stress response, which increases perioperative cardiovascular risk, especially in elderly subjects. Tegileridine fumarate is a novel μ-opioid receptor G protein-biased agonist. However, the optimal dose of tegileridine to suppress intubation-induced hemodynamic fluctuations during anesthesia induction remains unclear.\n\nThis is an open-label, single-center, age-stratified biased coin up-and-down sequential trial. Subjects undergoing elective surgery requiring tracheal intubation will be divided into young adult group (18-64 years) and elderly group (≥65 years). The primary objective is to determine the ED90 of intravenous tegileridine for inhibiting hemodynamic response to tracheal intubation using centered isotonic regression. Secondary outcomes include investigational-drug adverse events, serial hemodynamic parameters. This study will provide evidence for rational dosing of tegileridine in clinical anesthesia induction.",[59,60,61],"Tracheal Intubation","Anesthesia, General","Hemodynamics",[63,64,65],"Tegileridine","Hemodynamic Stress Response","ED90",{"date":36,"type":37},{"date":68,"type":21},"2026-09-01",{"date":70,"type":21},"2026-10-05",{"name":43,"class":44},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":45},"100642256","phase-4-oliceridine-vs-sufentanil-for-cough-during-anesthesia-induction-100642256","NCT07660380","Oliceridine vs Sufentanil for Cough During Anesthesia Induction","Oliceridine vs Sufentanil for Cough During General Anesthesia Induction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 99 years.\n* American Society of Anesthesiologists (ASA) physical status classification I, II, or III.\n* Body mass index (BMI) between 18.5 and 28.0 kg\u002Fm².\n* Scheduled for elective surgery under general anaesthesia.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Preoperative upper respiratory tract infection symptoms (e.g., cough, expectoration, or fever) or a history of bronchial asthma or other conditions associated with increased airway reactivity.\n* Severe cardiovascular disease (e.g., uncontrolled hypertension, recent myocardial infarction, or serious arrhythmia) or hepatic or renal dysfunction.\n* Long-term opioid use, defined as continuous opioid use for more than 2 weeks within the 3 months prior to surgery.\n* Known hypersensitivity to any study drug or anaesthetic agent used in this protocol.\n* Anticipated difficult airway requiring awake intubation.\n* Pregnancy or breastfeeding.",{"count":80,"type":21},62,[82],"PHASE4","Sufentanil is the most widely used opioid analgesic for general anaesthesia induction; however, rapid intravenous bolus injection frequently triggers sufentanil-induced cough (SIC). In high-risk patients, SIC can cause abrupt elevation of intracranial and intraocular pressure and severe haemodynamic instability, posing a meaningful safety risk during the induction period.\n\nOliceridine, the first G protein-biased μ-opioid receptor agonist approved by the Food and Drug Administration in 2020, provides analgesia through μ-receptor activation while substantially reducing β-arrestin-2 recruitment. This biased signalling profile is hypothesised to raise the excitation threshold of airway C-fibres and thereby reduce the incidence of cough.\n\nThis prospective, single-centre, randomised, double-blind, parallel-group controlled trial directly compares oliceridine with sufentanil for general anaesthesia induction with respect to cough incidence, cough severity, haemodynamic responses, and perioperative safety, with the aim of providing evidence-based guidance for opioid selection during induction.",[27,85],"Anesthesia",[87,88,89,90,91],"Oliceridine","Sufentanil","Sufentanil-induced cough","G protein-biased agonist","Anesthesia induction","RECRUITING","2026-07-18",{"date":95,"type":37},"2026-07-21",{"date":97,"type":37},"2026-06-27",{"date":99,"type":21},"2026-07-28",{"name":43,"class":44},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100645564","two-point-versus-single-point-serratus-anterior-plane-block-for-post-thoracoscopic-surgery-analgesia-100645564","NCT07700823","Two-Point Versus Single-Point Serratus Anterior Plane Block for Post-Thoracoscopic Surgery Analgesia","Comparison of Ultrasound-Guided Two-Point Combined vs Single-Point Serratus Anterior Plane Block for Postoperative Analgesia in Thoracoscopic Surgery: A Prospective Observational Cohort Study","Inclusion Criteria:\n\n* Aged 18 to 85 years at enrollment, regardless of sex\n* American Society of Anesthesiologists (ASA) physical status grade I to III\n* Scheduled for elective unilateral video-assisted thoracoscopic surgery\n* Planned to receive ultrasound-guided SAPB for routine perioperative analgesia\n* Able to understand study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Local infection or skin lesion at the block puncture site\n* Known hypersensitivity or allergy to amide local anesthetics\n* Preexisting sensory abnormality in the chest wall surgical area\n* Chronic opioid use for \\> 3 months, history of chronic pain syndrome, or history of opioid abuse\n* Severe coagulopathy (international normalized ratio \\> 1.5 or platelet count \\\u003C 80 × 10⁹\u002FL)\n* Cognitive impairment or inability to cooperate with postoperative pain assessment\n* Refusal to provide written informed consent","85 Years",{"count":110,"type":21},88,"OBSERVATIONAL","Postoperative pain remains a common clinical challenge in patients undergoing video-assisted thoracoscopic surgery (VATS), impairing early recovery and increasing opioid consumption. The serratus anterior plane block (SAPB) is a widely used regional analgesic technique for thoracic surgery, but conventional single-point injection may have limited spread of local anesthetics, resulting in suboptimal analgesia in some patients. Preliminary anatomical evidence suggests that two-point combined SAPB may achieve wider dermatomal coverage and better analgesic efficacy.\n\nThis is a single-center, prospective observational cohort study conducted at Shanghai Pulmonary Hospital, China. A total of 88 adult patients scheduled for elective unilateral VATS will be consecutively enrolled and naturally assigned to either the two-point combined SAPB group (injection at the 3rd and 5th rib levels, total 30 ml local anesthetic) or the single-point SAPB group (injection at the 5th rib level, 30 ml local anesthetic) according to routine clinical practice.\n\nThe primary outcome is the verbal rating scale (VRS) pain score on coughing at 24 hours postoperatively. Secondary outcomes include resting and dynamic pain scores at multiple time points, cumulative opioid consumption at 24 and 48 hours, incidence of postoperative nausea and vomiting, block-related complications, length of hospital stay, and Quality of Recovery-15 (QoR-15) scores. This study aims to provide clinical evidence for optimizing perioperative analgesic strategies for thoracoscopic surgery.",[114,115,116,117],"Lung Cancer","Pain","Video-Assisted Thoracoscopic Surgery","Serratus Anterior Plane Block","2026-07-08",{"date":120,"type":37},"2026-07-14",{"date":122,"type":21},"2026-08-01",{"date":124,"type":21},"2026-09-05",{"name":43,"class":44},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100642014","phase-4-fospropofol-disodium-versus-propofol-for-patient-satisfaction-in-ureteroscopy-100642014","NCT07659132","Fospropofol Disodium Versus Propofol for Patient Satisfaction in Ureteroscopy","Fospropofol Disodium Versus Propofol on Patient Satisfaction in Patients Undergoing Ureteroscopy：A Randomized Controlled Trial","Inclusion Criteria:\n\n* Undergoing elective ureteroscopic surgery\n* Aged between 18 and 90 years old\n* American Society of Anesthesiologists (ASA) physical status classification grade I to III\n\nExclusion Criteria:\n\n* Known allergy to propofol, fospropofol or their excipients\n* Severe cardiopulmonary insufficiency\n* Hepatic and renal dysfunction.Hepatic or renal insufficiency. Hepatic dysfunction: alanine aminotransferase (ALT) \\> 50 U\u002FL, or aspartate aminotransferase (AST) \\> 40 U\u002FL, or total bilirubin (TBIL) ≥ 19 μmol\u002FL; Renal dysfunction: serum creatinine (Cr) \\> 112 μmol\u002FL, or blood urea nitrogen (BUN) \\> 7.1 mmol\u002FL, or receiving dialysis within 28 days before surgery.\n* Pregnancy, lactation, potential pregnancy or planned pregnancy\n* Subjects who refuse to participate",{"count":134,"type":21},190,[82],"This single-center single-blind randomized trial compares fospropofol disodium and propofol for anesthesia in elective ureteroscopy patients. A total of 190 eligible adults will be randomly divided into two groups at 1:1 ratio with identical intraoperative maintenance protocols. The primary outcome is 24-hour postoperative anesthesia satisfaction assessed by ISAS scale; secondary and safety endpoints include injection pain, intraoperative hemodynamic events and various perioperative adverse reactions. This study explores the clinical efficacy and safety of the two sedatives to guide rational clinical medication.",[138,139],"Anesthesia for Urologic Endoscopic Surgery","Urinary Calculi",[141,142,143,144,145],"fospropofol disodium","propofol","ureteroscopy","anesthesia satisfaction","sedation","2026-06-19",{"date":148,"type":37},"2026-06-24",{"date":150,"type":21},"2026-06-26",{"date":152,"type":21},"2026-09-26",{"name":43,"class":44},""]